FENC logo

FENC Fennec Pharmaceuticals Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$13.33
-0.25 (-1.84%)

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the n…

Market Cap: $470.62Mwww.fennecpharma.com

Price

No data yet.

Social Signal Score

56
5d
—
30d
58
3 mentions
—
60d
58
3 mentions
—
90d
51
4 mentions
—
news: 4

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 0Sell 0Strong Sell 0
Avg price target$17+27.5%
Low $16Median $16High $19
Current Consensus

Revenue

$19.61M
$0.00$8.46M$16.92M$25.38M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.13
$-0.16–$-0.09
4 analysts
FY2026
$0.36
$0.23–$0.45
4 analysts
FY2027
$1.00+181% YoY
$0.72–$1.25
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jeffrey S. Hackman
Sector
Healthcare
Industry
Biotechnology
Employees
35
Beta
1.21
Country
US
Piotroski score
8 / 9 (Strong)
Altman Z-score
6.52
www.fennecpharma.com